Close Menu

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte on Monday reported a 13 percent increase in its fourth quarter net loss as higher personnel-related spending pushed up overall costs.

For the three-month period ended December 31, OncoCyte's net loss rose to $4.5 million, or $.11 per share, versus $4.0 million, or $.13 per share, in the same period the year before.

The Alameda, California-based company did not generate any revenue in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.